Biogen Analysis - 7823 Words

Executive Summary Biogen is a global biotechnology company headquartered in Cambridge, Massachusetts. Biogen is engaged in the research and development of biopharmaceuticals for human health care. Its main product is Avonex, a drug for the treatment of Multiple Sclerosis. Eighty-two percent of its revenues in 2000 came from the sale of this sole product. Biogen is also involved in the research of drugs for psoriasis, Crohn s disease, congestive heart failure, and cancer. Biogen believes that its success is based on its employees, and its corporate culture reflects this belief. Its culture is embedded in its corporate values. These values consist of hiring the highest quality employees, flexibility in work, leadership, and†¦show more content†¦Some 10% of the pharmaceutical market value is now generated by sales of biologicals - such as vaccines, insulin, EPO (erythropoetin), blood clotting factors, interferons and other cytokines. It is estimated by some (notably Ernst and Young) that over 50% of drugs on the market will be biological within 20 years. Another economic characteristic within the industry is the high cost of equipment. Much of the scientific equipment has to be on the cutting edge, making it quite expensive. Many small biotechnology firms are now setting up exclusive production and marketing relationships with the bigger pharmaceutical companies in order to have access to the latest equipment along with research and development capital support. Pharmaceutical companies, which traditionally have focused on chemical approaches to treating disease, have become increasingly supportive of biotech RD in their own labs, in partnerships with biotech firms, and through acquisitions of biotech firms. Alliances in the biotech industry doubled to nearly 250 between 1998 and 2000. Biotechnology is definitely a growing field. The number of U.S. biotech companies has increased to over 1,500, while the number of employees has nearly doubled from 79,000 in 199 3 to nearly 115,000 in 1999. The number of patents granted to biotechnology companies has tripled from nearly 3,000 per year in the early 1990 s to more than 9,000 inShow MoreRelatedAntegren Case Study8261 Words   |  34 PagesJOSHUA MARGOLIS THOMAS DELONG TERRY HEYMANN Antegren: A Beacon of Hope As Jim Mullen, CEO of Biogen Idec, drove into work on February 19, 2004, he considered both the tremendous hope and stiff challenge generated by the company the previous day. The company had announced its intention to submit an application to the U.S. Food and Drug Administration (FDA) seeking approval for Antegren, a drug that Biogen Idec was developing in partnership with Elan to treat multiple sclerosis (MS). While the patientRead MoreUsing the Mid Text Function/Moving and Copying Spreadsheets /Flow Charts Using Text Boxes and Auto Shapes1792 Words   |  8 Pages* * * * 2. As of June 2008, what is the value of the synergies Roche anticipates from a merger with Genentech? Assess the value of the synergies per share of Genentech. Please use a 9% weighted average cost of capital in your analysis. (2 pts) * * * * * Value of synergies: | | | | | | | | | | | | WACC | 9% | | | | | | | | | | |    | 2009 | 2010 | 2011 | 2012 | 2013 and thereafter | FCF | $138.05 | $362.36 | $436.47 |Read MoreDamodaran Book on Investment Valuation, 2nd Edition398423 Words   |  1594 Pagesthe valuation should be considered before decisions are made on its basis. For instance, a self-valuation done by a target firm in a takeover is likely to be positively biased. While this does not make the valuation worthless, it suggests that the analysis should be viewed with skepticism. The Biases in Equity Research The lines between equity research and salesmanship blur most in periods that are characterized by â€Å"irrational exuberance†. In the late 1990s, the extraordinary surge of market valuesRead MorePharmaceutical Industry : The Best Performing Industry, Based On Stock Performance1525 Words   |  7 Pagesindustry analysis, the biotechnology industry has been the best performing industry, based on stock performance. In each of the last four years the biotechnology industry has outperformed the market by at least 20% (44.1% in 2013) This success can be largely attributed to the advancement and success rate of biotech industry’s drug approvals which reached 41 in 2014, the highest since 53 in 1996, and is expected to keep this trend for at least the next three years. According to the SP analysis, peakRead MoreFinancial Management and Analysis2206 Words   |  9 PagesFinancial Management and Analysis Table of Contents Introduction 3 Presentation of the companies 3 Ratio analysis of the companies 5 Profitability ratios 5 Liquidity ratios 7 Efficiency ratios 9 Gearing ratios 11 Investment ratios 12 Ratio analysis strengths and weaknesses 14 â€Æ' Introduction Financial analysis involves the use of various financial statements, which perform several functions. Basics of financial analysis consist of a balance sheet and income statement.Read MoreA Wall Street Journal Article Essay1529 Words   |  7 PagesLangreth, Keller and Cannon (2016) published an analysis of U.S. pharmaceutical company pricing practices in Bloomberg titled, â€Å"Decoding Big Pharma’s Secret Drug Prices.† The authors write, â€Å"The pharmaceutical industry has long said that list prices aren’t a reliable indicator of what Americans pay for prescription drugs because the big [purchasers of drugs], including health insurers and pharmacy benefit managers, negotiate discounts. But a Bloomberg analysis of 39 medicines with global sales of moreRead MoreAnalysis Of Eli Lilly Co s Disease Essay1082 Words   |  5 Pagesgrow significantly if a disease-modifying treatment entered the space. The AD Companies You Should Know Although there are an abundant number of Phase I and II trials for AD, the number declines rapidly by Phase III. Let’s overview Lilly(LLY), Biogen (BIIB), Axovant (AXON), Merck (MRK), and AB Sciences (AB) to better understand five companies with AD Phase III trials underway. LLY has been a hot discussion topic among pharma investors. Solanezumab ( LY20602430) is the company’s main candidateRead MoreCase Study16130 Words   |  65 PagesKitchenware Company 38 Individual change 38 Team change 38 Organizational change 39 Leading change 39 Case study 4: Biogen Idec 40 Case study text: Biogen Idec 40 The change 42 Data gathering and option generation 43 Affiliates and culture change 43 Criteria for good change 44 The transition 45 Case study questions: Biogen Idec 46 Individual change 46 Team change 46 Organizational change 47 Leading change 47 Case study 1: AsterRead MoreThe medicines corporation case1267 Words   |  6 Pagesbreakeven point analysis to address this problem. The equation will be used here is listed as following: Q * (BEP - VC) - FC = 0 The direct variable cost is $40 per dose after the Medicine Company contracted out production to UCB. As for the fixed cost, we should take into account the amortization period. We noted the patent of Angiomax will be expired in 2010 which means there will be 10 years protected period. The total fixed cost includes the following: Table 2.2 Breakeven Analysis of Angiomax Read MoreOrphan Drug Market Development And Manufacturing Of Products1622 Words   |  7 Pagesmaintain its position within its current rare disease market, but also to continue to grow its product portfolio within the Orphan Drug market. Industry Competitive Forces Porter’s five forces analysis was performed to analyze the level of competition within the Orphan Drug industry (See Exhibit 1). This analysis focused on the assessment of the threat of new entrants, threat of substitute treatments, bargaining power of both the customer and suppliers, and the industry rivalry for Sanofi Genzyme. The